Lipoprotein(a) linked to elevated cardiovascular risk despite standard treatment

New data analyzing more than 20,000 patients from three major NIH studies show that elevated Lipoprotein(a) [Lp(a)] is associated with residual cardiovascular risk and warrants aggressive risk reduction. Researchers presented the data at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions and the Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI) Summit in Montreal.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup